The differential gene was obtained by identifying RNA‐Seq in clinical tissues of cervical cancer, and IGF2BP3 was identified as the common target gene for ATL III to act on HeLa and SiHa cells. This evidence concerns the gene IGF2BP3 and cervical carcinoma.